ublituximab
Showing 26 - 32 of 32
Chronic Lymphocytic Leukemia Trial in Israel, United States (Ublituximab, Ibrutinib)
Completed
- Chronic Lymphocytic Leukemia
- Ublituximab
- Ibrutinib
-
Huntsville, Alabama
- +87 more
Apr 25, 2022
Chronic Lymphocytic Leukemia Trial in Worldwide (Obinutuzumab, Ublituximab, TGR-1202)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Obinutuzumab
- +3 more
-
Huntsville, Alabama
- +153 more
Aug 19, 2022
DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Ublituximab, Umbralisib, Bendamustine)
Terminated
- Diffuse Large B-Cell Lymphoma
- +4 more
- Ublituximab
- +2 more
-
Birmingham, Alabama
- +167 more
Jul 20, 2022
Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma Trial in United States (Ublituximab + TGR-1202, Ublituximab + TGR-1202 +
Completed
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
- Ublituximab + TGR-1202
- +2 more
-
Huntsville, Alabama
- +5 more
Nov 4, 2019
Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia Trial in United States (Ublituximab)
Completed
- Non-Hodgkins Lymphoma
- +6 more
- Ublituximab
-
Huntsville, Alabama
- +7 more
Oct 1, 2019
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder Trial in Baltimore (Ublituximab)
Completed
- Neuromyelitis Optica
- Neuromyelitis Optica Spectrum Disorder
- Ublituximab
-
Baltimore, MarylandJohns Hopkins University School of Medicine
Jun 5, 2019